Abstract
ObjectiveTo investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK).MethodsWe performed a prospective cohort study in which baricitinib 4 mg daily was prescribed to...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
